Other equities research analysts have also issued reports about the company. Wells Fargo & Co lowered Gilead Sciences from an “outperform” rating to a “market perform” rating in a research report on Monday. Cantor Fitzgerald upped their price target on Gilead Sciences from $87.00 to $88.00 and gave the company an “overweight” rating in a research report on Friday, October 26th. Guggenheim assumed coverage on Gilead Sciences in a research report on Monday, December 17th. They set a “buy” rating and a $86.00 price target on the stock. Raymond James set a $90.00 price objective on Gilead Sciences and gave the stock a “buy” rating in a research note on Tuesday, February 5th. Finally, BidaskClub downgraded Gilead Sciences from a “buy” rating to a “hold” rating in a research note on Wednesday, November 21st. One analyst has rated the stock with a sell rating, ten have assigned a hold rating, ten have given a buy rating and one has given a strong buy rating to the company. Gilead Sciences has a consensus rating of “Buy” and a consensus price target of $86.85.
GILD stock opened at $67.62 on Tuesday. The company has a current ratio of 3.36, a quick ratio of 3.29 and a debt-to-equity ratio of 1.09. The company has a market cap of $87.28 billion, a P/E ratio of 11.00, a PEG ratio of 66.65 and a beta of 1.19. Gilead Sciences has a 12-month low of $60.32 and a 12-month high of $82.71.
Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Monday, February 4th. The biopharmaceutical company reported $1.44 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $1.70 by ($0.26). The firm had revenue of $5.80 billion for the quarter, compared to analyst estimates of $5.52 billion. Gilead Sciences had a net margin of 24.65% and a return on equity of 37.03%. The business’s revenue was down 2.6% on a year-over-year basis. During the same period in the prior year, the company posted $1.78 earnings per share. Sell-side analysts expect that Gilead Sciences will post 6.23 earnings per share for the current year.
In other news, Director John C. Martin sold 50,000 shares of the stock in a transaction on Monday, December 3rd. The stock was sold at an average price of $71.20, for a total value of $3,560,000.00. Following the completion of the transaction, the director now owns 2,877,762 shares of the company’s stock, valued at $204,896,654.40. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Corporate insiders own 1.16% of the company’s stock.
Several large investors have recently added to or reduced their stakes in GILD. BlackRock Inc. increased its holdings in shares of Gilead Sciences by 1.4% during the 1st quarter. BlackRock Inc. now owns 105,236,053 shares of the biopharmaceutical company’s stock valued at $7,933,746,000 after acquiring an additional 1,438,806 shares during the last quarter. Vanguard Group Inc. increased its holdings in shares of Gilead Sciences by 1.1% during the 3rd quarter. Vanguard Group Inc. now owns 97,167,329 shares of the biopharmaceutical company’s stock valued at $7,502,290,000 after acquiring an additional 1,071,619 shares during the last quarter. Vanguard Group Inc increased its holdings in shares of Gilead Sciences by 1.1% during the 3rd quarter. Vanguard Group Inc now owns 97,167,329 shares of the biopharmaceutical company’s stock valued at $7,502,290,000 after acquiring an additional 1,071,619 shares during the last quarter. Capital Research Global Investors increased its holdings in shares of Gilead Sciences by 22.5% during the 3rd quarter. Capital Research Global Investors now owns 69,854,968 shares of the biopharmaceutical company’s stock valued at $5,393,502,000 after acquiring an additional 12,818,301 shares during the last quarter. Finally, State Street Corp increased its holdings in shares of Gilead Sciences by 4.5% during the 4th quarter. State Street Corp now owns 60,448,831 shares of the biopharmaceutical company’s stock valued at $4,328,739,000 after acquiring an additional 2,587,072 shares during the last quarter. 80.03% of the stock is owned by institutional investors.
Gilead Sciences Company Profile
Gilead Sciences, Inc discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.
Featured Article: How to read a candlestick chart
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.